The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Sterecyt     [2- [(8R,9R,10S,11S,13S,14S,17R)- 11,17...

Synonyms: Stereocyt, PREDNIMUSTINE, Prednimustina, Prednimustinum, SureCN8246, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of LEO 1031


High impact information on LEO 1031


Chemical compound and disease context of LEO 1031


Biological context of LEO 1031


Anatomical context of LEO 1031


Associations of LEO 1031 with other chemical compounds


Gene context of LEO 1031

  • The resulting particles contained on average 338 mol prednimustine/mol apoB and exhibited a diameter that was ca. 2.5 times that of native LDL [21].
  • However, no intact prednimustine was recovered in the MT fractions [28].

Analytical, diagnostic and therapeutic context of LEO 1031


  1. Risk of leukemia following treatment for non-Hodgkin's lymphoma. Travis, L.B., Curtis, R.E., Stovall, M., Holowaty, E.J., van Leeuwen, F.E., Glimelius, B., Lynch, C.F., Hagenbeek, A., Li, C.Y., Banks, P.M. J. Natl. Cancer Inst. (1994) [Pubmed]
  2. A rare case of prednimustine-induced myoclonus. Monnerat, C., Gander, M., Leyvraz, S. J. Natl. Cancer Inst. (1997) [Pubmed]
  3. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Tirelli, U., Zagonel, V., Errante, D., Serraino, D., Talamini, R., De Cicco, M., Carbone, A., Monfardini, S. J. Clin. Oncol. (1992) [Pubmed]
  4. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I., Solal-Céligny, P. J. Clin. Oncol. (1997) [Pubmed]
  5. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Unterhalt, M., Herrmann, R., Tiemann, M., Parwaresch, R., Stein, H., Trümper, L., Nahler, M., Reuss-Borst, M., Tirier, C., Neubauer, A., Freund, M., Kreuser, E.D., Dietzfelbinger, H., Bodenstein, H., Engert, A., Stauder, R., Eimermacher, H., Landys, K., Hiddemann, W. Leukemia (1996) [Pubmed]
  6. Waldenström's macroglobulinemia complicated with acute myeloid leukemia. Report of a case and review of the literature. Rodríguez, J.N., Fernández-Jurado, A., Martino, M.L., Prados, D. Haematologica (1998) [Pubmed]
  7. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Tirelli, U., Zagonel, V., Sorio, R., Errante, D., Talamini, R., Carbone, A., Monfardini, S. Semin. Hematol. (1994) [Pubmed]
  8. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone. Hiddemann, W., Unterhalt, M., Koch, P., Nahler, M., Herrmann, R., van de Loo, J. Eur. J. Cancer (1991) [Pubmed]
  9. Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer. Smyth, J.F., Beattie, G.J., Stewart, M.E., Cowie, V.J., Smart, G.E., Livingstone, J.R., Leonard, R.C. Ann. Oncol. (1991) [Pubmed]
  10. Comparative pharmacokinetics of chlorambucil and prednimustine after oral administration. Loos, U., Musch, E., Malek, M., Riedel, E. Oncology (1991) [Pubmed]
  11. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group. Gandara, D.R., Wold, H.G., Redmond, J., Kohler, M., Reynolds, R., Wong, P., Forsythe, J., Fisher, K., Lewis, B. Semin. Oncol. (1986) [Pubmed]
  12. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen. Mouridsen, H.T., Andersson, M., Pedersen, L. Semin. Oncol. (1986) [Pubmed]
  13. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Santoro, A., Viviani, S., Valagussa, P., Bonfante, V., Bonadonna, G. Semin. Oncol. (1986) [Pubmed]
  14. A preliminary analysis of combination therapy with vincristine, adriamycin, and prednimustine (VAP) in advanced breast cancer: a phase II study. Lehnert, M., Biffl, G., Wascher, H., Jordis-Lohausen, K., Wählby, S. Semin. Oncol. (1986) [Pubmed]
  15. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. Murphy, G.P., Gibbons, R.P., Johnson, D.E., Prout, G.R., Schmidt, J.D., Soloway, M.S., Loening, S.A., Chu, T.M., Gaeta, J.F., Saroff, J., Wajsman, Z., Slack, N., Scott, W.W. J. Urol. (1979) [Pubmed]
  16. Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone. Sayed, A., Hove, W.V., Vermeulen, A. Oncology (1981) [Pubmed]
  17. Some metabolic aspects of a nitrogen mustard of prednisolone. Kirdani, R.Y., Murphy, G.P., Sandberg, A.A. Oncology (1978) [Pubmed]
  18. Long-term toxicology effects of prednimustine in comparison with chlorambucil, prednisolone, and chlorambucil plus prednisolone in Sprague-Dawley rats. Berger, M.R., Habs, M., Schmähl, D. Semin. Oncol. (1986) [Pubmed]
  19. On the clinical pharmacology of prednimustine. Plym Forshell, G., Gunnarsson, P.O., Liljekvist, J. British journal of clinical pharmacology. (1983) [Pubmed]
  20. Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line. Hartley-Asp, B., Gunnarsson, P.O., Liljekvist, J. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  21. Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture. Lundberg, B. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  22. Prednimustine in adult acute myeloid leukaemia. Brandt, L., Könyves, I. Cancer Chemother. Pharmacol. (1979) [Pubmed]
  23. Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. Musch, E., Malek, M., Peter-Katalinic, J., Egge, H., Rink, H., Lathan, B., Riedel, E. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  24. Third-line salvage chemotherapy in Hodgkin's disease. Bonadonna, G., Viviani, S., Valagussa, P., Bonfante, V., Santoro, A. Semin. Oncol. (1985) [Pubmed]
  25. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Pickel, H., Lahousen, M., Petru, E., Stettner, H., Hackl, A., Kapp, K., Winter, R. Gynecol. Oncol. (1999) [Pubmed]
  26. Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay. Oppitz, M.M., Musch, E., Malek, M., Rüb, H.P., von Unruh, G.E., Loos, U., Mühlenbruch, B. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  27. Does long-term application of granulocyte colony-stimulating factor adversely influence overall survival in patients with ovarian cancer? A clinical study. Peters-Engl, C., Medl, M., Denison, U., Sevelda, P., Leodolter, S., Petru, E. Anticancer Res. (2001) [Pubmed]
  28. Comparison of the cytotoxic effect of prednimustine in cultured cells with high or low levels of metallothionein. Endresen, L. Acta pharmacologica et toxicologica. (1984) [Pubmed]
  29. Prednimustine treatment in malignant lymphomas. Szántó, I., Fleischmann, T., Eckhardt, S. Oncology (1989) [Pubmed]
  30. A randomized comparative study of prednimustine and doxorubicin in patients with metastatic breast cancer. Allegra, J.C. Semin. Oncol. (1986) [Pubmed]
  31. Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas. Roncadin, M., Arcicasa, M., Bortolus, R., Trovó, M.G., Carbone, A., Tirelli, U., De Paoli, A., Franchin, G., Grigoletto, E. Cancer Invest. (1991) [Pubmed]
  32. 'Aggressive' low grade lymphocytic lymphomas can be identified by flow cytometric S-phase determinations. Lindh, J., Jonsson, H., Lenner, P., Roos, G. Hematological oncology. (1992) [Pubmed]
WikiGenes - Universities